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Abstract
Quinolone and b-lactam resistance mechanisms and clonal rela-
tionships were characterized among Escherichia coli isolates resis-
tant to ciproﬂoxacin and extended-spectrum cephalosporins
associated with human extra-intestinal infections in Rome. The
E. coli. ST131 clone was found to be prevalent. This clone invariably
carried a speciﬁc pattern of substitutions in the topoisomerase
genes and all isolates but one produced CTX-M-15. One ST131
isolate produced SHV-12. The new ST131 variant described here
is of particular concern because it combines ﬂuoroquinolone
resistance and chromosomally encoded CTX-M-15.
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Extra-intestinal pathogenic Escherichia coli (ExPEC) isolates
are involved in a wide spectrum of human diseases, including
urinary-tract infections (UTIs), septicaemia and neonatal
meningitis, and the management of such infections has
become complicated as a result of combined ﬂuoroquinolone
and extended-spectrum cephalosporin resistance [1].
Sixty-four ciproﬂoxacin-resistant extra-intestinal isolates of
E. coli isolates (MIC ‡4 mg/L), each obtained from different
patients in Rome, Italy, between March and September 2006,
at the San Camillo Forlanini Hospital and at the BIOS Diagnos-
tic Laboratory, from blood (23 isolates) and urine (41 isolates)
samples, respectively, were included in this study. During this
period, 852 cases of human septicaemia occurred in the hospi-
tal, 68 of which were caused by E. coli, whereas, of the 1061
community-acquired UTIs, 323 were caused by E. coli.
MICs and conﬁrmation of the presence of extended-spec-
trum b-lactamases (ESBLs) were performed by E-test (Bio-
Me´rieux S.A., Marcy l’Etoile, France) and breakpoints were
interpreted based on CLSI susceptibility criteria [2]. The vast
majority of isolates were highly resistant to ciproﬂoxacin
(MIC90 ‡ 32 mg/L), irrespective of the isolation site (blood
or urine). The prevalence of ciproﬂoxacin resistance was
higher among bloodstream isolates than among those from
UTIs (23/68; 33.8% vs. 41/323; 12.7%). Fifteen out of 64 iso-
lates (23%) were conﬁrmed to be ESBL producers (Table 1).
The 64 isolates were screened for plasmid-mediated
quinolone resistance (PMQR) genes [3–6]. Two isolates
(3.1%) possessed both qnrB1 and aac(6’)-Ib-cr genes, whereas
12 (18.8%) carried the aac(6’)-Ib-cr gene only, conﬁrming that
the aac(6’)-Ib-cr gene appeared to be more prevalent than
the qnr genes [7]. Identiﬁcation of the b-lactamase-encoding
genes (blaCTX-M, blaSHV, blaTEM and blaOXA-1) was carried out
in a subgroup of 18 isolates including all the ESBL-producing
and the PMQR- positive isolates [8–10]. Of the 15 ESBL
producers, 14 contained blaCTX-M-15 and one harboured
blaSHV-12. The percentage of CTX-M-15-producing E. coli was
signiﬁcantly higher among blood isolates than among UTI iso-
lates (10/23; 43.5% vs. 4/41; 9.8%; p 0.0017).
Plasmids were transferred by transformation (MAX Efﬁ-
ciency DH5a; Invitrogen, Milan, Italy) or conjugation (RifR
E. coli CSH26) and assigned to plasmid families [11]. The
ESBL and PMQR genes were all located on plasmids, except
in strains IN6 and IN33 both from cases of septicaemia.
Strain IN6 carried plasmids, although the blaCTX-M-15 gene
was identiﬁed within the chromosome by the PFGE-I-CeuI
method [12], whereas, in strain IN33, this gene was located
on both chromosome and IncF plasmid, suggesting the pres-
ence of more than one copy of the ESBL gene within the
same cell. In all the remaining isolates, the blaCTX-M-15 gene
was identiﬁed on plasmids belonging to the IncF group (50–
200 kb), carrying more than one repF replicon, as previously
described (Fig. 1) [13]. Strains IN21 and IN44 both carried
the qnrB1 gene on IncHI2 plasmids.
The quinolone resistance determining region (QRDR) of
the gyrA, gyrB and parC genes was examined for the ESBL
producers and PMQR-positive isolates (Table 1) [14]. All the
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isolates exhibited double mutations in GyrA at codons Ser83
and Asp87. The same Ser83 ﬁ Leu amino acid change was
detected in each strain, whereas different mutations
occurred at the Asp87 codon, generating the Asp87 ﬁ Asn
or Asp87 ﬁ Gly or Asn87 ﬁ Tyr amino acid changes. Further
single or double mutations were detected at the Ser80 and/
TABLE 1. Genotypic and phenotypic characteristics of extended-spectrum b-lactamase-producing and/or qnr -and aac(6’)-Ib-cr-
positive isolates
Isolate
GyrA
ParC
Type
GyrA ParC
qnr
aac(6’)
-Ib-cr
b-lactamase genes MIC (mg/L)
Ser83 Asp87 Ser80 Glu84 blaTEM blaCTX-M blaSHV blaOXA-1 CIP LV CRO CTX
UR 3 A Leu Asn Ile Val ) + blaTEM-1 blaCTX-M-15 – blaOXA-1 ‡32 ‡32 ‡64 ‡64
UR 14 A Leu Asn Ile Val ) + blaTEM-1 blaCTX-M-15 – blaOXA-1 ‡32 ‡32 ‡64 ‡64
UR 40 A Leu Asn Ile Val ) + blaTEM-1 blaCTX-M-15 – blaOXA-1 ‡32 ‡32 ‡64 ‡64
IN 30 A Leu Asn Ile Val ) + blaTEM-1 blaCTX-M-15 – blaOXA-1 ‡32 ‡32 ‡64 ‡64
IN 31 A Leu Asn Ile Val ) + blaTEM-1 blaCTX-M-15 – blaOXA-1 ‡32 ‡32 ‡64 ‡64
IN 34 A Leu Asn Ile Val ) + blaTEM-1 blaCTX-M-15 – blaOXA-1 ‡32 ‡32 ‡64 ‡64
IN 40 A Leu Asn Ile Val ) + blaTEM-1 blaCTX-M-15 – blaOXA-1 ‡32 ‡32 ‡64 ‡64
IN 16 A Leu Asn Ile Val ) + – blaCTX-M-15 – blaOXA-1 ‡32 ‡32 ‡64 ‡64
IN 33 A Leu Asn Ile Val ) + – blaCTX-M-15
a – blaOXA-1 ‡32 ‡32 ‡64 ‡64
IN 6 A Leu Asn Ile Val ) ) blaTEM-1 blaCTX-M-15
a – – ‡32 ‡32 ‡64 ‡64
IN 36 A Leu Asn Ile Val ) ) – blaCTX-M-15 – – ‡32 24 ‡64 ‡64
IN 22 A Leu Asn Ile Val ) ) – – blaSHV-12 – ‡32 32 32 4
UR 36 B Leu Asn Ile Glu ) + blaTEM-1 – – – ‡32 ‡32 0.064 0.125
UR 41 B Leu Asn Ile Glu ) + – blaCTX-M-15 – blaOXA-1 ‡32 ‡32 ‡64 ‡64
IN 12 B Leu Asn Ile Glu ) ) blaTEM-1 blaCTX-M-15 – – ‡32 ‡32 ‡64 ‡64
IN 21 C Leu Tyr Ile Val qnrB1 + blaTEM-1 – – blaOXA-1 ‡32 ‡32 0.094 0.38
IN 43 D Leu Gly Ser Lys ) + – blaCTX-M-15 – blaOXA-1 ‡32 8 ‡64 ‡64
IN 44 E Leu Tyr Ile Gly qnrB1 + blaTEM-1 – – blaOXA-1 ‡32 ‡32 0.125 0.25
CIP, ciproﬂoxacin; LV, levoﬂoxacin; AM, ampicillin; CRO, ceftriaxone; CTX, cefotaxime.
UR, isolate from urine; IN, isolate from blood.
aChromosomal integration of the blaCTX-M-15 gene.
FIG. 1. Genetic relatedness among 18 extended-spectrum b-lactamase (ESBLs)-producing and/or qnrB1- and aac(6’)-Ib-cr-positive E. coli isolates.
Cluster analysis of the pulsed ﬁeld gel electrophoresis (PFGE) patterns, phylogenetic groups and multilocus sequence typing genotyping, together
with the main characteristics of the resistance genotypes are shown. DNA fragments were analysed with the Diversity Database Fingerprinting
Software, version 2 (Bio-Rad Laboratories, Hercules, CA, USA). The band tolerance used was 1.0%. Similarity analysis of the PFGE patterns was
performed with Dice’s coefﬁcient and clustering by the unweighted pair group method with arithmetic mean. Strains with a coefﬁcient of similar-
ity value ‡80% were considered to belong to the same PFGE clonal group (clusters A and B in the boxes). *blaCTX-M-15 gene integrated in the
chromosome. PBRT, polymerase chain reaction-based replicon typing.
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or Glu84 codons of ParC (Ser80 ﬁ Ile and Glu84 ﬁ Val or
Glu84 ﬁ Gly). No change in QRDR of GyrB was observed.
The different patterns of amino acid substitutions were
designated as patterns A to E; the predominant was pattern
A (12/18; 66.7%) (Table 1).
Genetic relatedness among 18 ESBL-producing and PMQR
positive isolates was assessed by XbaI-pulsed ﬁeld gel
electrophoresis (PFGE) analysis (New England Biolabs, Inc.,
Ipswich, MA, USA), phylogenetic grouping and multilocus
sequence typing (MLST) (Fig. 1) [15,16].
Most of the isolates (12/18; 66.7%) belonged to the phylo-
genetic group B2, and seven isolates constituted a clonal
group named PFGE-cluster A (Fig. 1). MLST analysis
identiﬁed seven distinct STs; the predominant was ST131,
comprising 11 isolates (11/18; 61%), including the seven of
PFGE-cluster A. ST648 was assigned to the two qnrB1-posi-
tive strains (PFGE-cluster B). Most of the ST131 isolates
were CTX-M-15-producers (10/11) and aac(6’)-Ib-cr-positive
(8/11). Notably, all the ST131 isolates showed the character-
istic GyrA/ParC pattern A, irrespective of the ESBL type or
the presence or absence of PMQR genes.
Over the past year, several reports have described the
emergence and dissemination across the globe of uropathogen-
ic and invasive E. coli ST131 isolates producing CTX-M-15 and,
in several cases, showing ciproﬂoxacin resistance by unidenti-
ﬁed mechanisms [17]. Our results demonstrated that the E. coli
ST131 clone had a high level of ciproﬂoxacin resistance associ-
ated with a speciﬁc QRDR mutation pattern. The same pattern
was found in other European ST131 isolates, including a high
level resistant one where it was associated with OMP loss,
whereas a slightly different pattern occurred in ST131 isolates
from Korea, supporting the hypothesis of a different origin for
these microorganisms [18,19]. Of note, in our study, two cip-
roﬂoxacin-resistant ST131 isolates from cases of septicaemia
further evolved by chromosomal integration of the blaCTX-M-15
gene. Despite the chromosomal location of ESBL genes in
Enterobacteriaceae being regarded as a very rare event, the inte-
gration of the blaCTX-M-15 gene is apparently not so exceptional,
having been reported in E. coli from four continents and in
Salmonella from internationally adopted children [13,20]. The
chromosomal integration of the blaCTX-M-15 gene might
contribute to the stable maintenance and diffusion of this resis-
tance gene in particularly successful clones.
We also identiﬁed one ST131 strain that has acquired the
blaSHV-12 gene and displayed the same topoisomerase pattern
of the other ST131 isolates. The acquisition of b-lactamases
other than CTX-M-15 in ST131 has recently been reported
in Japan and Norway. In Japan, ST131 produced CTX-M-2-
group enzymes because this CTX-M group is predominant
in Asia, whereas, in Norway, it produced CMY-2 [21,22].
These observations suggest that ST131 have had a world-
wide dissemination even before the acquisition of ESBL
genes, and this clonal strain can abruptly change the preva-
lence of infections with ESBL-producing E. coli within a coun-
try [21]. To conclude, the new variant of the ST131 clone
described here is of particular concern because it combines
both chromosomally encoded ESBLs and topoisomerase
gene mutations, within the successful genetic context of the
ST131 clone.
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Abstract
Three Pseudomonas putida strains containing blaVIM-2 were iso-
lated from an inanimate surface of a female ward sanitary facility
in the Hospital Infante D. Pedro, Aveiro. A novel class 1 integ-
ron was found in strain Pp2 (aacA4/blaVIM-2/aac6¢-IIc disrupted by
an insertion sequence IS1382), and strain Pp1 was found to
carry a class 1 integron (aacA7/blaVIM-2/aacC1/aacA4), which is
described for the ﬁrst time in this species. Strain PF1 carries a
class 1 integron associated with a Tn5090-like transposon, con-
stituting the ﬁrst ﬁnding of this type of arrangement in a strain
from Portugal. This association highlights further dissemination
of blaVIM-2 in environmental hospital isolates.
Keywords: Antibiotic resistance, class 1 integrons, Gram-nega-
tive bacteria, hospital environment, Tn5090-like transposon
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Pseudomonas putida is a Gram-negative opportunistic patho-
gen that is rarely involved in human infections [1] and is
therefore considered to be a low-grade pathogen [2–4].
Carbapenems are broad-spectrum antibiotics that are fre-
quently used in the treatment of Pseudomonas spp. infections
[3]. Consequently, the emergence of metallo-b-lactamases
(MBLs) of the IMP or VIM type among non-fermenting Gram-
negative bacteria is becoming frequent and represents an epi-
demiological risk, as these enzymes confer resistance not only
to carbapenems, but to virtually all b-lactams [4,5]. Moreover,
blaIMP and blaVIM are usually carried on integrons, in association
with aminoglycoside resistance cassettes. These mobile ele-
ments are easily spread horizontally between different species,
owing to their association with transposons or plasmids [4–7].
The blaVIM-2 gene was ﬁrst described in a Pseudomonas aeru-
ginosa [8] isolate in France. Currently, the VIM-type enzymes
constitute the second most dominant group of b-lactamases,
and have been reported in different species from 23 countries
worldwide [4,9], with the alleged ‘index’ strain being a
Portuguese P. aeruginosa isolate recovered in 1995 [10,11]. The
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